Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160

Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on Mirum Pharmaceuticals (NASDAQ: MIRM) and increased the price target from $145 to $160. This adjustment reflects a positive outlook for the company's performance in the market.